Cargando…

Intravaginal Combination Therapy of Acetic and Lactic Acid in premenopausal women with recurrent vulvovaginal candidiasis: A randomized, double-blind placebo-controlled feasibility trial

BACKGROUND: Recurrent vulvovaginal candidiasis management primarily entails azole therapy used as required or as an extended daily or weekly maintenance therapy for 6 months or more. Unfortunately, relapse within 3–6 months of ceasing maintenance therapy is experienced for more than half the patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Strydom, Moira Bradfield, Khan, Sohil, Walpola, Ramesh L, Testa, Chris, Ware, Robert S, Tiralongo, Evelin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467244/
https://www.ncbi.nlm.nih.gov/pubmed/37635435
http://dx.doi.org/10.1177/17455057231194138
_version_ 1785099073142915072
author Strydom, Moira Bradfield
Khan, Sohil
Walpola, Ramesh L
Testa, Chris
Ware, Robert S
Tiralongo, Evelin
author_facet Strydom, Moira Bradfield
Khan, Sohil
Walpola, Ramesh L
Testa, Chris
Ware, Robert S
Tiralongo, Evelin
author_sort Strydom, Moira Bradfield
collection PubMed
description BACKGROUND: Recurrent vulvovaginal candidiasis management primarily entails azole therapy used as required or as an extended daily or weekly maintenance therapy for 6 months or more. Unfortunately, relapse within 3–6 months of ceasing maintenance therapy is experienced for more than half the patients, for whom indefinite treatment is required. OBJECTIVES: To explore the feasibility of trial design examining a prophylaxis treatment to prevent recurrent vulvovaginal candidiasis symptomatic episodes and reduce adverse effects. STUDY DESIGN: A double-blinded randomized controlled feasibility trial was conducted in Australia. Women with recurrent vulvovaginal candidiasis were enrolled. METHODS: An intravaginal prophylaxis application of lactic acid and acetic acid (Intravaginal Combination Therapy of Acetic and Lactic Acid) was compared with placebo. Primary outcomes comprised recruitment and retention, compliance to study medications and study assessments. Secondary outcomes included the reduction of symptomatic recurrence over the trial period and the acceptability, satisfaction, safety and tolerability of the intervention. The feasibility of quality-of-life measures was also explored. RESULTS: Fifteen participants were enrolled and randomized (active = 9, placebo = 6). Consent rate was 23.4%. Eight participants were lost to follow-up (active = 5, placebo = 3). Forty-seven per cent of participants (n = 7) were 100% compliant with the intervention, six of which completed the trial with good assessment compliance. The blinding process was effective. The study demonstrated a reduction in relapse in both active and placebo groups with only four participants across both groups reporting symptomatic episodes while enrolled. The intervention demonstrated good tolerability. Quality-of-life data showed minimal variance with a high quality-of-life measure. CONCLUSION: This trial assesses the feasibility of conducting a large-scale study exploring the efficacy of the Intravaginal Combination Therapy of Acetic and Lactic Acid intravaginal intervention and hints on the importance of psychological support through appropriate disease-specific communication and clinical attention. Consideration of the reported recruitment challenges, the inclusion of suitable quality-of-life measures and digital data collection is warranted for adaptation to a fully powered trial.
format Online
Article
Text
id pubmed-10467244
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-104672442023-08-31 Intravaginal Combination Therapy of Acetic and Lactic Acid in premenopausal women with recurrent vulvovaginal candidiasis: A randomized, double-blind placebo-controlled feasibility trial Strydom, Moira Bradfield Khan, Sohil Walpola, Ramesh L Testa, Chris Ware, Robert S Tiralongo, Evelin Womens Health (Lond) Original Research Article BACKGROUND: Recurrent vulvovaginal candidiasis management primarily entails azole therapy used as required or as an extended daily or weekly maintenance therapy for 6 months or more. Unfortunately, relapse within 3–6 months of ceasing maintenance therapy is experienced for more than half the patients, for whom indefinite treatment is required. OBJECTIVES: To explore the feasibility of trial design examining a prophylaxis treatment to prevent recurrent vulvovaginal candidiasis symptomatic episodes and reduce adverse effects. STUDY DESIGN: A double-blinded randomized controlled feasibility trial was conducted in Australia. Women with recurrent vulvovaginal candidiasis were enrolled. METHODS: An intravaginal prophylaxis application of lactic acid and acetic acid (Intravaginal Combination Therapy of Acetic and Lactic Acid) was compared with placebo. Primary outcomes comprised recruitment and retention, compliance to study medications and study assessments. Secondary outcomes included the reduction of symptomatic recurrence over the trial period and the acceptability, satisfaction, safety and tolerability of the intervention. The feasibility of quality-of-life measures was also explored. RESULTS: Fifteen participants were enrolled and randomized (active = 9, placebo = 6). Consent rate was 23.4%. Eight participants were lost to follow-up (active = 5, placebo = 3). Forty-seven per cent of participants (n = 7) were 100% compliant with the intervention, six of which completed the trial with good assessment compliance. The blinding process was effective. The study demonstrated a reduction in relapse in both active and placebo groups with only four participants across both groups reporting symptomatic episodes while enrolled. The intervention demonstrated good tolerability. Quality-of-life data showed minimal variance with a high quality-of-life measure. CONCLUSION: This trial assesses the feasibility of conducting a large-scale study exploring the efficacy of the Intravaginal Combination Therapy of Acetic and Lactic Acid intravaginal intervention and hints on the importance of psychological support through appropriate disease-specific communication and clinical attention. Consideration of the reported recruitment challenges, the inclusion of suitable quality-of-life measures and digital data collection is warranted for adaptation to a fully powered trial. SAGE Publications 2023-08-27 /pmc/articles/PMC10467244/ /pubmed/37635435 http://dx.doi.org/10.1177/17455057231194138 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research Article
Strydom, Moira Bradfield
Khan, Sohil
Walpola, Ramesh L
Testa, Chris
Ware, Robert S
Tiralongo, Evelin
Intravaginal Combination Therapy of Acetic and Lactic Acid in premenopausal women with recurrent vulvovaginal candidiasis: A randomized, double-blind placebo-controlled feasibility trial
title Intravaginal Combination Therapy of Acetic and Lactic Acid in premenopausal women with recurrent vulvovaginal candidiasis: A randomized, double-blind placebo-controlled feasibility trial
title_full Intravaginal Combination Therapy of Acetic and Lactic Acid in premenopausal women with recurrent vulvovaginal candidiasis: A randomized, double-blind placebo-controlled feasibility trial
title_fullStr Intravaginal Combination Therapy of Acetic and Lactic Acid in premenopausal women with recurrent vulvovaginal candidiasis: A randomized, double-blind placebo-controlled feasibility trial
title_full_unstemmed Intravaginal Combination Therapy of Acetic and Lactic Acid in premenopausal women with recurrent vulvovaginal candidiasis: A randomized, double-blind placebo-controlled feasibility trial
title_short Intravaginal Combination Therapy of Acetic and Lactic Acid in premenopausal women with recurrent vulvovaginal candidiasis: A randomized, double-blind placebo-controlled feasibility trial
title_sort intravaginal combination therapy of acetic and lactic acid in premenopausal women with recurrent vulvovaginal candidiasis: a randomized, double-blind placebo-controlled feasibility trial
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467244/
https://www.ncbi.nlm.nih.gov/pubmed/37635435
http://dx.doi.org/10.1177/17455057231194138
work_keys_str_mv AT strydommoirabradfield intravaginalcombinationtherapyofaceticandlacticacidinpremenopausalwomenwithrecurrentvulvovaginalcandidiasisarandomizeddoubleblindplacebocontrolledfeasibilitytrial
AT khansohil intravaginalcombinationtherapyofaceticandlacticacidinpremenopausalwomenwithrecurrentvulvovaginalcandidiasisarandomizeddoubleblindplacebocontrolledfeasibilitytrial
AT walpolarameshl intravaginalcombinationtherapyofaceticandlacticacidinpremenopausalwomenwithrecurrentvulvovaginalcandidiasisarandomizeddoubleblindplacebocontrolledfeasibilitytrial
AT testachris intravaginalcombinationtherapyofaceticandlacticacidinpremenopausalwomenwithrecurrentvulvovaginalcandidiasisarandomizeddoubleblindplacebocontrolledfeasibilitytrial
AT wareroberts intravaginalcombinationtherapyofaceticandlacticacidinpremenopausalwomenwithrecurrentvulvovaginalcandidiasisarandomizeddoubleblindplacebocontrolledfeasibilitytrial
AT tiralongoevelin intravaginalcombinationtherapyofaceticandlacticacidinpremenopausalwomenwithrecurrentvulvovaginalcandidiasisarandomizeddoubleblindplacebocontrolledfeasibilitytrial